---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-APN-201"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: APC-APN-201. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 26 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence/apc-apn-201"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-APN-201

<a id="heading-3.1.5"></a>

## 3.1.5 APC-APN-201

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Pharmacokinetics, efficacy, tolerability, and safety with concomitant GLP-1 receptor agonists

> “This study evaluated the pharmacokinetics (PK), efficacy, tolerability and safety of AD109 when co-administered with glucagon-like peptide-1 receptor agonists (GLP-1 RA) in participants with OSA and obesity.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-3.1.5.1-2"></a>

#### Registered official title

> “Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Registered study dates and sites

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2024-05-20” |
| Primary completion (actual) | “2024-12-26” |
| Number of locations | “This study has 4 locations” |
| Alabama site | “Anniston, Alabama, United States, 36207 Pinnacle Research Group, LLC” |
| Florida site | “Jacksonville, Florida, United States, 32256 Clinical Neuroscience Solutions, Inc” |
| North Carolina site | “Monroe, North Carolina, United States, 28112 Monroe Biomedical Research” |
| Tennessee site | “Memphis, Tennessee, United States, 38119 Clinical Neuroscience Solutions, Inc” |

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Open-label, parallel-arm, 6-week phase 2 design

> “This was an open-label, parallel-arm, 6-week phase 2 study of AD109 in participants with mild-to-severe OSA and obesity, administered either alone or while remaining on a stable maintenance dose of a GLP-1 RA (tirzepatide, semaglutide, or liraglutide).”
> “The study consisted of a screening period, 2-day single dose PK period, followed by a 6-week AD109 dosing period.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-3.1.5.3-2"></a>

#### Arms defined by concomitant GLP-1 receptor agonist use

> “Study APC-APN-201 is an open-label, parallel-arm, 6 weeks study of AD109 in participants with OSA and obesity.”
> “All study procedures, including open-label dosing of AD109, are the same for both arms; the arms differ only in concomitant GLP-1 use.”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.3-3"></a>

#### Registered design details

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.3-4"></a>

#### Sponsor

> “This study was supported by Apnimed, Inc.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Inclusion: age, body mass index, and REI4 range on home sleep apnea testing

> “Between 18-75 years of age at the time of informed consent.”
> “BMI between 27 and 43 kg/m2 for men, or 45 kg/m2 for women, inclusive.”
> “Mean Respiratory Event Index (REI4) (Hypopneas defined by 4% oxygen desaturation) of >5 and <45. REI is determined as a mean number collected across 2 nights of testing initiated at Visit 2; ≤ 25% central or mixed apneas (as proportion of total apneas and hypopneas)”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.4-2"></a>

#### Inclusion: stable GLP-1 receptor agonist dose or eligibility for one

> “One arm consists of patients concomitantly taking tirzepatide, semaglutide or liraglutide, and a second comparator arm consists of patients not taking any GLP drug but who otherwise would meet the criteria for prescribing a GLP-1 (i.e., BMI≥27).”
> “The participants on GLP-1 must be on a stable maintenance dose that has remained unchanged for at least four weeks prior to enrollment.”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.4-3"></a>

#### Inclusion: prior OSA devices withheld

> “Participants with a history of using devices for OSA treatment, including Continuous Positive Airway Pressure (CPAP), oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 2 weeks prior to first HSAT and are not used during participation in the study.”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.4-4"></a>

#### Exclusion: insomnia, urinary, glaucoma, psychiatric, and bariatric surgery criteria

> “Current bothersome symptoms of insomnia (difficulty initiating or maintaining sleep, as distinct from unrefreshing sleep or other symptoms attributable to OSA).”
> “Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying”
> “Narrow angle glaucoma.”
> “Attempted suicide within 1 year prior to screening, or current suicidal ideation.”
> “Subjects with a history of gastric weight loss surgery (i.e., sleeve gastrectomy, gastric bypass, adjustable gastric banding, biliopancreatic diversion)”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.4-5"></a>

#### Exclusion: blood pressure threshold

> “Systolic blood pressure up to 140 mm Hg or diastolic blood pressure up to 90 mm Hg is allowed in participants not currently treated with antihypertensives.”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### AD109 tablet strength

> “AD109, an investigational oral anti-apneic neuromuscular modulator, combines in one tablet the novel antimuscarinic aroxybutynin (2.5 mg) with the selective norepinephrine reuptake inhibitor atomoxetine (75 mg).”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-3.1.5.5-2"></a>

#### Registered arms and administration

> “Twenty patients who are taking GLP-1 at time of enrollment will be treated with AD109”
> “Twenty patients who are not taking a GLP-1 will be treated with AD109 only”
> “Oral administration at bedtime”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.5-3"></a>

#### Permitted GLP-1 receptor agonists

> “Tirzepatide (Mounjaro®, Zepbound®): doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg can be given once weekly by subcutaneous injection”
> “Other doses prescribed by a physician are acceptable if a stable dose is maintained for 4 weeks or more.”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Incidence of Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary outcome: spontaneously reported adverse events at 6 weeks

> “Primary Objective (Adverse Events)”
> “General safety and tolerability will be assessed between treatment cohorts using the occurrence of spontaneously reported adverse events (AEs) at 6 weeks”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.6.1-2"></a>

##### Efficacy outcome: REI4 responder at week 5 by home sleep apnea test

> “The proportion of participants achieving ≥50% reduction in respiratory event index based on 4% hypopnea desaturation assessed with home sleep apnea test at Week 5”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Planned enrollment by arm

> “A total of approximately 40 participants will be enrolled in the 2 arms:”
> “Each arm is composed of approximately 20 participants.”

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="topic-3.1.5.7.1-2"></a>

##### Actual enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “Enrollment (Actual) 40” |

Source: [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Pharmacokinetic analysis: noncompartmental analysis and mixed-effects model

> “Plasma PK for aroxybutynin and atomoxetine, including maximum plasma concentration (Cmax) and exposures (AUClast and AUCinf), were derived by noncompartmental analysis and evaluated using a mixed-effects model.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Participants enrolled and treated by arm

> “Forty participants were enrolled and received AD109 (n=22) or AD109+GLP-1 RA (n=18).”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### REI4 responder rate at week 5 with and without a GLP-1 receptor agonist

> “The proportion of participants achieving ≥50% reduction in respiratory event index based on 4% hypopnea desaturation assessed with home sleep apnea test at Week 5 in the AD109 and AD109+GLP-1 RA arms were similar (33.3% vs 29.4%, respectively).”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-3.1.5.8.3-2"></a>

##### Pharmacokinetics: geometric mean ratios with versus without a GLP-1 receptor agonist

> “Geometric mean ratios (GMR; AD109+GLP-1 RA/AD109 alone [90% CI]) of aroxybutynin for Cmax, AUClast, and AUCinf were 100.6 (68.0–148.8), 142.0 (102.1–197.5), and 152.7 (111.0–210.1), respectively.”
> “GMR of atomoxetine for Cmax, AUClast, and AUCinf were 67.0 (51.0–88.1), 81.9 (57.0–117.7), and 78.2 (51.3–119.1), respectively.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Treatment-emergent adverse events, serious events, and deaths

> “Treatment-emergent adverse events (TEAEs) were reported by 85% of participants with the majority being mild-to-moderate severity.”
> “TEAEs of dry mouth, decreased appetite, nausea, and constipation were reported with higher incidence in the AD109 alone arm.”
> “No clinically meaningful trends were detected in mean changes from baseline in lab values, physical examination variables, or vital signs.”
> “No deaths or serious TEAEs occurred.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-3.1.5.8.5-2"></a>

##### Authors' safety conclusion

> “AD109 was generally safe and well-tolerated in both treatment arms of this phase 2 trial, without large differences in PK when co-administered with GLP-1 RA.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

- Design: open-label, 6-week phase 2 study with no placebo arm; the arms differ only in concomitant GLP-1 receptor agonist use, while the registry lists the allocation as randomized.
- Size: 40 participants at 4 U.S. sites, with 22 receiving AD109 alone and 18 receiving AD109 with a GLP-1 receptor agonist, against about 20 planned per arm.
- Population: ages 18 to 75, BMI 27 to 43 (men) or 45 (women) kg/m2, and REI4 above 5 and below 45 on home sleep apnea testing. Exclusions included bothersome insomnia or bladder outlet obstruction, narrow angle glaucoma, and prior gastric weight loss surgery. Prior device users enrolled after 2 weeks without use.
- Endpoints: the primary outcome was spontaneously reported adverse events. Efficacy was the proportion with at least 50% REI4 reduction on home sleep apnea testing at week 5, reported as 33.3% and 29.4%.
- Reporting: results are available only from a congress abstract, without baseline characteristics or PROs.
- Sponsor: the abstract states the study was supported by Apnimed.

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293); [ClinicalTrials.gov NCT06400615](https://clinicaltrials.gov/study/NCT06400615)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
